盐酸罗比卡因腰丛-坐骨神经阻滞的药代动力学研究

Pharmacokinetics of ropivacaine for combined lumbar plexus-sciatic nerve blockade

目的采取反相高效液相法测定盐酸罗比卡因血药浓度,观察该药腰丛-坐骨神经阻滞病人的药代动力学指标.方法8例择期单下肢手术病人,使用0.375%盐酸罗比卡因行腰丛-坐骨神经阻滞,分别在给药前及给药后5、10、15、20、25、30、40、50、60、90、120、180、240、360、720、1 440 min采取静脉血.采用Agilent Zorbax SB-C18反相色谱柱(4.6 mm× 250 mm,5 μm)分离,并用3P97计算药代动力学参数.结果线性范围10～8 000 ng/ml,仪器灵敏度AUFS为1 ng/ml,所得药代动力学参数结果为:Cmaxi(3.09±0.89)mg/L,Cmax2(3.84±1.58)mg/L,t1/2 Kα(7.56±4.65)min,t1/2β(890.3±365.8)min.结论腰丛-坐骨神经阻滞后,用反相高效液相色谱法行血浆盐酸罗比卡因浓度的测定,方法稳定、简便、灵敏度高,适用于该药在此种条件下的药代动力学研究.

Objective A RP-HPLC method for determination of ropivacaine in plasma was developed, and the pharmacokinetics of ropivacaine was investigated in combined lumbar plexus-sciatic nerve blockade. Methods Eight patients undergoing lower-extremity surgery accepted combined lumbar plexus-sciatic nerve block, 0.375% ropivacaine 3mg/kg was injected. Blood samples were taken before operation and at 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 180, 240, 360, 720 and 1440 min after drug administration for determination of plasma ropivacaine concentration. Agilent Zorbax SB-C18（4.6 mm×250 mm, 5 μm）as a stationary phase and the pharmacokinetic parameters were calculated by 3P97. Results The linear range was from 10-8000 ng/ml, the AUFS is 1 ng/ml, and the pharmacokinetic parameters are Cmax1 （3.09 ± 0.89） mg/L, Cmax2 （3.84 ± 1.58） mg/L, t1/2 Ka（7.56±4.65） min,t1/2β（890.3±365.8） rain. Conclusion A RP-HPLC is a stable, simple and sensitive methord for determination of plasma ropivacaine concentration during combined lumbar plexussciatic never blockade.